Malaria Vaccine R78C: Oxford and Serum Institute Join Forces

A Global Collaboration Against Malaria

The University of Oxford and the Serum Institute of India (SII) have inked a licensing deal to produce and manufacture R78C, a new malaria vaccine.The agreement is likely to help speed up efforts to eradicate malaria, which still kills millions of people, especially children, in sub-Saharan Africa.

What Is the R78C Vaccine?

R78C aims to combat Plasmodium falciparum, the most deadly malaria parasite.

R78C is the first malaria vaccine to use a multi-stage strategy to target the parasite at different stages of its life cycle. It contains two blood-stage antigens:

• RIPR
• CyPRA

The vaccine will target the parasite at different developmental points to:

• Generate a stronger immune response
• Reduce disease severity
• Limit transmission

This is a major development in malaria vaccine strategies.

Why the Oxford-Serum Partnership is Key

SII's presence is vital for its unique manufacturing capacity. As the world's largest volume vaccine producer, it can:

Scale up production efficiently
Ensure affordability
Facilitate global roll-out

The partnership is also a continuation of previous work, such as the creation of the R21/Matrix-M malaria vaccine, underscoring a commitment to innovation and access.

R78C's Approach to Vaccines

Existing vaccines, such as R21/Matrix-M, focus on the sporozoite stage of malaria, the initial stage of infection.

R78C, however:

• Tackles the blood stage , when the disease is severe
• Seeks to prevent complications and death
• May work with other vaccines to provide greater immunity

Scientists hope a multistage vaccine may help with long-term immunity and address issues like vaccine 'decline'.

A Vaccine to Reduce Malaria's Burden

Malaria is a significant disease burden, particularly in developing countries. An improved vaccine could:

• Reduce disease burden and deaths
• Increase survival rates of children
• Support long-term eradication efforts

The deal also showcases India's emerging importance in the field of health through mass production of low-cost vaccines.

Next Steps in Development

R78C is in the research and clinical trial stage. The agreement will support:

• Faster progression through clinical trials
• Manufacturing readiness
• Future large-scale distribution

The vaccine would undergo several stages of testing